Cargando…
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
BACKGROUND: This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and elderly patients with recurrent advanced soft tissue sarcoma (STS). METHODS: Data from 350 adults with STS treated in five phase II trials with trabectedin were divided in...
Autores principales: | Cesne, A L, Judson, I, Maki, R, Grosso, F, Schuetze, S, Mehren, M V, Chawla, S P, Demetri, G D, Nieto, A, Tanovic, A, Blay, J-Y |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790176/ https://www.ncbi.nlm.nih.gov/pubmed/24022187 http://dx.doi.org/10.1038/bjc.2013.524 |
Ejemplares similares
-
Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008) -
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
por: Jones, Robin L., et al.
Publicado: (2021) -
Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015) -
Trabectedin for soft tissue sarcoma
Publicado: (2021) -
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)